top of page

Developing therapies to improve quality of life in Alzheimer's disease




Our mission

Our mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia  read more 

Our vision

We aim to improve the quality of life for patients, reduce distress for caregivers and support patients' families. Through cutting-edge research, rigorous clinical trials and collaboration with experts, we are dedicated to delivering the best-in-class treatment for neuropsychiatric symptoms of dementia. 


Our ultimate vision is to restore dignity and quality of life of individuals affected by neuropsychiatric symptoms of dementia , provide comprehensive relief, and transform the way dementia care is perceived and managed worldwide.




October 25, 2022

The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry

October 11, 2022

Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist


October 26, 2021

Exciva raises €9 million in Series A round led by Andera Partners (full press release)


bottom of page